[Allogeneic haematopoietic cell transplantation for diffuse large B cell lymphoma: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

{"article_title":"[Allogeneic haematopoietic cell transplantation for diffuse large B cell lymphoma: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].","author":"Gauthier J, Chantepie S, Bouabdallah K, Jost E, Nguyen S, Gac AC, Damaj G, Dul\u00e9ry R, Michallet M, Delage J, Lewalle P, Morschhauser F, Salles G, Yakoub-Agha I, Cornillon J","journal_title":"Bulletin du cancer","issn":"1769-6917","isbn":"","publication_date":"2017-12-01","volume":"104","issue":"12S","first_page":"S131","page_count":"","accession_number":"29173980","doi":"10.1016\/j.bulcan.2017.10.018","publisher":"Elsevier","doctype":"Consensus Development Conference","subjects":"Hematopoietic Stem Cell Transplantation standards; Lymphoma, Large B-Cell, Diffuse therapy; Allografts; France; Humans; Lymphoma, Large B-Cell, Diffuse pathology; Societies, Medical","interest_area":["Oncology"],"abstract":"Despite great improvements in the outcome of patients with lymphoma, some may still relapse or present with primary refractory disease. In these situations, allogeneic hematopoietic cell transplantation is a potentially curative option, this is true particularly in the case of after autologous stem cell transplantation if remission can be achieved. Recently, novel agents such as anti-PD1 and BTK inhibitors have started to challenge the use of allogeneic hematopoietic cell transplantation for relapsed or refractory lymphoma. During the 2016 annual workshop of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), we performed a comprehensive review of the literature published in the last 10 years and established guidelines to clarify the indications and transplant modalities in this setting. This section specifically reports on our conclusions regarding diffuse large B cell lymphoma. Copyright \u00a9 2017. Published by Elsevier Masson SAS.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=29173980","isPdfLink":false,"isSAML":false,"an":"29173980","number_other":"","type_pub":"","issn_electronic":"1769-6917","languages":"French","language":"fre","date_entry":"Date Created: 20171128 Date Completed: 20171228 Latest Revision: 20171228","date_update":"20240104","titleSource":"Bulletin du cancer [Bull Cancer] 2017 Dec; Vol. 104 (12S), pp. S131-S135. Date of Electronic Publication: 2017 Nov 22.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2017-12-01","description":"Despite great improvements in the outcome of patients with lymphoma, some may still relapse or present with primary refractory disease. In these situations, allogeneic hematopoietic cell transplantation is a potentially curative option, this is true particularly in the case of after autologous stem cell transplantation if remission can be achieved. Recently, novel agents such as anti-PD1 and BTK inhibitors have started to challenge the use of allogeneic hematopoietic cell transplantation for relapsed or refractory lymphoma. During the 2016 annual workshop of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), we performed a comprehensive review of the literature published in the last 10 years and established guidelines to clarify the indications and transplant modalities in this setting. This section specifically reports on our conclusions regarding diffuse large B cell lymphoma.<br \/> (Copyright © 2017. Published by Elsevier Masson SAS.)","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&scope=site&db=mdl&AN=29173980&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"Gauthier J, Chantepie S, Bouabdallah K, Jost E, Nguyen S, Gac AC, Damaj G, Dul\u00e9ry R, Michallet M, Delage J, Lewalle P, Morschhauser F, Salles G, Yakoub-Agha I, Cornillon J"}